Clinical Trials Directory

Trials / Unknown

UnknownNCT06278064

Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis

Plasma Extracellular Vesicle Quantitative Proteomic Analysis for Early Diagnosis of Upper Gastrointestinal Cancers

Status
Unknown
Phase
Study type
Observational
Enrollment
562 (estimated)
Sponsor
Beijing Friendship Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

This study constitutes a case-control investigation employing a retrospective approach. Plasma samples from individuals with esophageal cancer, benign esophageal diseases, gastric cancer, benign gastric diseases, and a healthy control group were systematically collected. Advanced Data-Independent Acquisition (DIA) proteomics and single-vesicle membrane protein detection techniques were employed to quantify protein content within exosomes. Specific protein biomarkers indicative of early-stage upper gastrointestinal tumors were identified. External validation of these protein markers was conducted using Parallel Reaction Monitoring (PRM) technology on an independent validation cohort. The objective is to establish protein marker predictions for early diagnosis of upper gastrointestinal tumors and prognostication of therapeutic efficacy.

Detailed description

This study employs a multicenter, retrospective cohort design, collecting and analyzing plasma and tissue exosome protein data from patients with upper gastrointestinal tumors (Stage I-II), upper gastrointestinal benign diseases, and a healthy control group who have visited Beijing Friendship Hospital, and other relevant sub-center hospitals over the past five years. Concurrently, relevant clinical and pathological information is recorded. Samples from the training cohort undergo traditional quantitative exosome proteomic analysis (Data-Independent Acquisition, DIA) and single-vesicle membrane protein analysis (PBA). A comprehensive upper gastrointestinal tumor-specific exosome protein database is constructed, incorporating extensive information. Subsequently, bioinformatics methods are employed to conduct in-depth analysis of the extensive protein data, screening for proteins with high specificity for upper gastrointestinal tumors, capable of direct detection on the exosome membrane surface. By establishing and evaluating diagnostic models, we aim to quantify the diagnostic potential of these markers, providing a scientific basis for future early screening methods for upper gastrointestinal tumors. Finally, external validation of these protein markers in an independent validation cohort ensures their reliability and stability across different patient populations. The academic significance of this research lies in its thorough exploration of exosome proteomics in early cancer diagnosis, offering potential innovative breakthroughs for academic progress and clinical practice in this field.

Conditions

Interventions

TypeNameDescription
OTHERGastric CancerPatients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
OTHEREsophagus CancerPatients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer

Timeline

Start date
2024-02-01
Primary completion
2024-12-31
Completion
2025-06-30
First posted
2024-02-26
Last updated
2024-02-26

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06278064. Inclusion in this directory is not an endorsement.